

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, D.C. 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, D.C. 20510

RECEIVED
SECRETARY OF THE SENATE

02 AUG 12 PM 3:06

LOBBYING REPORT

Lobby Disclosure Act of 1995 (Section 5) — All Filers Are Required To Complete This Page

1. Registrant Name Hogan & Hartson L.L.P.			
2. Address <input type="checkbox"/> Check if different than previously reported Columbia Square, 555 Thirteenth Street, N.W. Washington DC 20004-1109			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Maruyama, Warren H. WHMaruyama@HHLAW.com	Telephone 202-637-5709	E-mail (optional)	5. Senate ID # 18422-1611
7. Client name <input type="checkbox"/> Self Pharmaceutical Research Manufacturers of America (PhRMA)			6. House ID # 30470157

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇒ Termination Date _____ 11. No Lobbying ☐

INCOME OR EXPENSES — Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>200,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 603 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
---	--

Signature W. H. Maruyama
Printed Name and Title Maruyama, Warren H. Partner

Date 7/22/02

LD-1 (REV. 6/98)

Registrant Name Hogan & Hartson L.L.P.

Client Name Pharmaceutical Research Man
of America (PhRMA)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which t
engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c
information as requested. Attach individual page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues
pharmaceutical trade, intellectual property rights, U.S.-Japan Enhanced De-Regulation;
Initiative;
China Permanent Normal Trade Relations (PNTR-H.R. 4444).

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
U.S. House of Representatives;
U.S. Senate;
Office of U.S. Trade Representative;
Department of Commerce;
Department of State;
NEC/NSC

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Archibald, Jeanne S.	Partner
Maruyama, Warren H.	Partner

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Printed Name and Title Maruyama, Warren H. Partner

Registrant Name Hogan & Hartson L.L.P.

Client Name Pharmaceutical Research Man
of America (PhRMA)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which t
engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each c**
information as requested. Attach individual page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 358, Medicare Prescription Drug and Modernization Act of 2001 and other legislation;
relating to Medicare prescription drug benefits

17. House(s) of Congress and Federal agencies contacted ☒ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Vickery, Ann Morgan	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Registrant Name Hogan & Hartson L.L.P.Client Name Pharmaceutical Research Man
of America (PhRMA)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each c** information as requested. Attach individual page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001;

H.R. 3448, Public Health Security and Bioterrorism Response Act of 2001;

S. 1715/S. 1765 Bioterrorism Preparedness Act of 2001;

S. 754, Drug Competition Act of 2001;

S. 812/ H.R. 1862, Greater Access to Affordable Pharmaceuticals Act of 2001

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States Senate;

U.S. House of Representatives;

Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Beier, David W.</u>	<u>Chief Domestic Policy Advisor for Vice Presid</u>
<u>Bultena, Lance D.</u>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Registrant Name Hogan & Hartson L.L.P.

Client Name Pharmaceutical Research Man
of America (PhRMA)**Information Update Page — Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client**ISSUE UPDATE**24. General lobbying issues previously reported that **no longer** apply**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of E (city and state or c

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the client or affiliated organization

Signature



Printed Name and Title Marivama Warren H. Partner

LD-2 (REV. 6/98)

LD-2 (REV. 6/98)